China Isotope & Radiation Corporation (1763) H1 2026 earnings summary

Executive summary

• Revenue for the first half of 2026 reached RMB2,993.8 million, up 4.4% year-over-year, driven by growth in nuclear medicines, nuclear medical equipment, and radioactive source and application segments.

• Net profit was RMB332.2 million, up 2.1% year-over-year; net profit attributable to the parent company was RMB159.0 million, down 1.2% due to tax adjustments, business restructuring, and exchange losses.

• Gross margin declined to 49.4% from 51.7% year-over-year, mainly due to changes in revenue structure.

• The Board proposed an interim dividend of RMB0.0994 per share, totaling RMB31.8 million, subject to shareholder approval.

Financial highlights

• Operating revenue: RMB2,993.8 million (up 4.4% year-over-year).

• Gross profit: RMB1,480.1 million (in line with prior year); gross margin: 49.4% (down 2.3 percentage points year-over-year).

• Net profit: RMB332.2 million (up 2.1% year-over-year); net profit attributable to parent: RMB159.0 million (down 1.2% year-over-year).

• Earnings per share: RMB0.5030.

• Total assets: RMB16,080.2 million; total liabilities: RMB7,732.5 million; total equity: RMB8,347.7 million as of 30 June 2026.

• Adjusted net gearing ratio: 35.6%; quick ratio: 1.5x.

• Capital expenditures: RMB245.8 million.

Outlook and guidance

• Plans to expand the nationwide network of pharmaceutical centers to 37, covering over 95% of the population.

• Focus on accelerating self-sufficiency in isotope supply, expanding the nuclear medicine industrial chain, and deepening smart nuclear medicine solutions and digital transformation.

• Continued investment in R&D, digital transformation, high-end equipment, and international market expansion.

• Strategic emphasis on extending, supplementing, and strengthening the industrial chain, scientific innovation, and market development.